IN THE SPOTLIGHT

Treatment Sequencing in EGFR-Mutant NSCLC

Treatment Sequencing in EGFR-Mutant NSCLC

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFRTM Inhibitor for NSCLC

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFR™ Inhibitor for NSCLC

BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFR™ Inhibitor for NSCLC

Aakash Desai: Updated OS From the Phase II PHAROS Study in BRAF V600E–Mutant NSCLC

Aakash Desai: Updated OS From the Phase II PHAROS Study in BRAF V600E–Mutant NSCLC

Practical Monitoring Strategies and Early Treatment Assessments in Patients with BRAF V600E-Mutant Metastatic NSCLC

Practical Monitoring Strategies and Early Treatment Assessments in Patients with BRAF V600E-Mutant Metastatic NSCLC

Safety Profile of Encorafenib + Binimetinib and Management of Key Toxicities When Treating Patients with BRAF V600E-Mutant Metastatic NSCLC

Safety Profile of Encorafenib + Binimetinib and Management of Key Toxicities When Treating Patients with BRAF V600E-Mutant Metastatic NSCLC

Rapidly evolving therapeutic advances for classical EGFR-mutant NSCLC

Rapidly evolving therapeutic advances for classical EGFR-mutant NSCLC